title: Transformation in the pharmaceutical industry--a systematic review of the literature.
abstract: The evolutionary development of pharmaceutical transformation was studied through systematic review of the literature. Fourteen triggers were identified that will affect the pharmaceutical business, regulatory science, and enabling technologies in future years. The relative importance ranking of the transformation triggers was computed based on their prevalence within the articles studied. The four main triggers with the strongest literature evidence were Fully Integrated Pharma Network, Personalized Medicine, Translational Research, and Pervasive Computing. The theoretical quality risks for each of the four main transformation triggers are examined, and the remaining ten triggers are described.
  The pharmaceutical industry is currently going through changes that affect the way it performs its research, manufacturing, and regulatory activities (this is termed pharmaceutical transformation). The impact of these changes on the approaches to quality risk management requires more understanding. In this paper, a comprehensive review of the academic, regulatory, and industry literature were used to identify 14 triggers that influence pharmaceutical transformation. The four main triggers, namely Fully Integrated Pharma Network, Personalized Medicine, Translational Research, and Pervasive Computing, were selected as the most important based on the strength of the evidence found during the literature review activity described in this paper. Theoretical quality risks for each of the four main transformation triggers are examined, and the remaining ten triggers are described.
authors.affiliation: School of Pharmacy and Biomolecular Sciences, Liverpool, John Moores University, Liverpool, UK.
authors.forename: Nader
authors.initials: N
authors.lastname: Shafiei
authors.forename: James L
authors.initials: JL
authors.lastname: Ford
authors.forename: Charles W
authors.initials: CW
authors.lastname: Morecroft
authors.forename: Paulo J
authors.initials: PJ
authors.lastname: Lisboa
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Taylor
authors.forename: Yusra
authors.initials: Y
authors.lastname: Mouzughi
mesh_terms: D002626:Chemistry, Pharmaceutical; D004345:Drug Industry; D006801:Humans; D007221:Industry; D012106:Research; D012308:Risk Management; D057170:Translational Research, Biomedical